Novo Nordisk's Obesity Drug CagriSema Beats Wegovy In Trial

Novo Nordisk’s experimental obesity drug CagriSema, designed to treat weight loss and type 2 diabetes, has delivered stronger results than its current blockbuster Wegovy in a major late-stage clinical trial, the company said today.

Individuals with uncontrolled type 2 diabetes reduced a mean of 14.2 percent of their body weight on CagriSema, versus 10.2 percent of their body weight on Wegovy, showed a study involving 68 weeks of REIMAGINE 2 study.

Better glycemic control of the patients on CagriSema was also demonstrated by an average percentage change in HbA1c, which was 1.91 percentage points (as compared to 1.76 percentage points with semaglutide alone, which is the active component of Wegovy). The research included thousands of adults who already had a prescription of standard diabetes treatment and compared the fixed-dose combination of cagrilintide and semaglutide with Wegovy and placebo.

Also Read: India's Hospitals Face Rising Risk of U.S.-Style Fee-for-Service

They have received new data that makes CagriSema a possible successor to Wegovy and an attractive prospect to physicians managing obese-related diabetes. The combination drug has been developed by acting on the pathways of hunger and glycemic control by combining cagrilintide that imitates amylin and semaglutide that is a GLP-1 agonist.

This outcome is a good sign to investors and those whose eyes are on the industry as Novo moves towards regulatory approval. Any change in the performance of CagriSema will change the competitive market on the weight-loss drug market, which is already heating up with the performance of Eli Lilly and others. Certain analysts believe that the regulators in the United States and Europe will likely consider submissions of the drug in the near future and it could provide the patients who have difficulties with obesity and diabetes with a new treatment.